BPC-157 Safety and Dosage Limits — Data Review

BPC-157 has no established safe dosage limit. No regulatory body has assessed its safety. There is no LD50 information available. This statement is included at the beginning of this article because the searches that brought people to this article, such as "BPC-157 max dose", "BPC-157 overdose", and "BPC-157 toxicity", deserve answers, including the answer of no information available.

BPC-157 Safe Dosage Limits - Not Established for Humans

Why No Regulatory Agency Has Set a Limit

Regulatory bodies such as the FDA, EMA, and TGA establish safe dosage limits based on finished clinical tests. These tests are conducted through a systematic approach: preclinical toxicology studies in multiple animal species, followed by Phase I dose-escalation studies are conducted in healthy human participants, and then Phase II and III efficacy tests are conducted. BPC-157 has not gone through any stage of this method in human beings.

Without Phase I data, there is no maximum tolerated dose. Without Phase II data, there is no therapeutic dose range. Without Phase III data, there is no approved indication or dosage regimen. The compound exists entirely outside the regulatory framework that defines "safe" doses for human use.

The Difference Between "No Toxicity Seen" and "Proven Safe"

Sikiric et al. (2010) conducted a review of the research on BPC-157 and concluded that the studies they evaluated found no evidence of toxicity (PMID 20166993). The conclusion has been repeatedly quoted as evidence that BPC-157 is safe. It isn’t.

If "no toxicity detected" means that researchers have not observed any harmful effect at specific doses on the specific species at the particular duration and at the given endpoints, "safe proved" means that an extensive system of procedures is implemented to detect toxicity at increasing doses and across various periods of time in various organs, in various species, and eventually humans. In the case of BPC-157 studies, the first statement has been confirmed but the second has not.

We think this distinction is the single most important point on this page.

Toxicology Data From Animal Studies

Overall, the table tells us the same thing: efficacy studies where there was no indication of adverse findings. The studies were not done as safety or toxicology studies. It is like checking whether a bridge was capable of carrying ten cars as opposed to determining the weight capacity of the bridge.

Acute Toxicity Studies - What Was Measured

Standard acute toxicity tests typically use one high dose that is monitored over two weeks for animal mortality, signs, body weight and gross necropsy at the end of the study. No BPC-157 article has used this design yet. The data which are somewhat similar to this standard design come from the tests of efficacy where animals received one injection and were evaluating only the desired endpoint.

Subchronic Exposure - Longest Durations Tested

As per the studies published on BPC-157, the treatment duration was long, lasting for at least several weeks. Sikiric et al. (2018) showed that studies could have treatment periods that could range from days to weeks in various experimental models (PMID 29879879). In regulatory toxicology, subchronic studies are those that last for either 28 or 90 days with detailed observations for the whole duration and analysis of the organs at the end.

There have been no published studies matching the relevant regulatory definition of subchronic toxicity studies for the BPC-157. The multi-week treatment studies in the literature were pharmacology experiments, not safety assessments.

LD50 and Therapeutic Index - Do They Exist for BPC-157?

No LD50 Published in Indexed Literature

The term LD50, refers to the dose that will kill half of the animals in a test. It is a simple way to measure how poisonous a substance can be. Most pharmacologically active compounds have a published LD50. For BPC-157, none has been reported. Sikiric et al. (2010) explicitly stated that no lethal dose could be established at the doses tested (PMID 20166993).

The unavailability of an LD50 can indicate any one of two things. It could mean that the substance is less toxic and a very high dose is needed to achieve fatalities or that the appropriate testing was not completed at all. Given the limited range of doses examined in the BPC-157 literature, the second interpretation appears more evidently plausible. We can’t dismiss the first option, but there are no adequate data to be supportive of it.

What That Means for Safety Margins

The therapeutic index of medication can be described as the ratio determined by the toxic dose divided by the effective dose. A higher ratio means that the drug has more distance between effective and harmful dose. The therapeutic index of aspirin is narrow and that of water soluble vitamins is normally wide.

With respect to BPC-157's therapeutic index, it is impossible to calculate it, as neither its toxic dose nor therapeutic dose has been defined yet. The phrase "BPC-157 possesses a good therapeutic index" appears in some Web sources but is not scientifically supported.

Theoretical Upper Bounds and Their Limits

Allometric Projections Are Not Safety Data

Certain methods try to determine a secure dose for humans by applying the highest dosage administered to rats without any harmful effect using the allometric method of body surface area. In most calculations, this is done by dividing 10 mcg/kg given to rats by 6.2, giving us around 1.6 mcg/kg for humans. This would mean that for a person weighing 70 kg, the effective dose would be about 112 mcg.

There are two significant flaws associated with the calculation in question. Firstly, the rat dose was not determined on the basis of proper experimentation as the maximum safe dose. It refers rather to an efficacy dose that fortunately coincidentally showed no adverse reactions. Secondly, although allometric changes correct for differences between species as far as their metabolic rates are concerned, they do not account for specificity of toxicity, receptor differences, and off-target reactions that might take place in each species.

Why Forum "Max Dose" Numbers Have No Basis

On the internet, it’s not unusual to see references to the dosages of BPC-157 ranging from 500 mcg to 1500 mcg as maximum safe dosage for humans, however, this does not have any reliable basis in reality. These figures seem to emanate from product marketing by the suppliers of BPC, a few reports of personal experiences with the compound, or meaningless calculations.

The statement "I took X mcg and am feeling fine" does not provide safety data and applies only in case you experience no adverse effects as indicated. The lack of symptoms does not indicate the absence of any effects on the function of organs, variations in blood chemistry, or any other factors that require laboratory tests for verification. We emphasize this point in order to inform the public accurately rather than to cause panic.